Unlisted biotech firm CureVac, which is due to receive German state backing, will become the second coronavirus vaccine developer to launch human trials of an experimental immunization in the country, two people familiar with the plans told Reuters on Tuesday. The clinical trial, which is scheduled to be announced on Wednesday, is the second clinical program to be approved by German vaccines regulator, the Paul Ehrlich Institute, following a study ...